Accelerating the Development of New Alpha Therapies for Cancer Treatment

加速癌症治疗新阿尔法疗法的开发

• 批准号: ST/T003162/1
• 负责人: Christian Diget
• 金额: $ 11.29万
• 依托单位: University of York
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=ST%2FT003162%2F1
• 关键词: Accelerating; Development; New; Alpha; Therapies

The overall aim of the present proposal is to take full advantage of the treatment potential of a new cancer therapy. This involves novel radiopharmaceuticals that incorporate alpha-emitting radioactive isotopes for cancer-specific targeted alpha therapy (TAT), which is expected to revolutionize cancer care. The development and implementation of this new treatment is, however, hindered and delayed due to the cumbersome detection of alpha emitters during the TAT pharmaceutical development. We will change this by developing a new advanced alpha sensor for the pharmaceutical industry. The sensor will facilitate and greatly simplify monitoring, benchmarking, and quality control of the TAT radiopharmaceutical. The sensor will be principally based on UK detector technology which has been developed under an STFC-funded research programme for nuclear structure and nuclear astrophysics experiments at TRIUMF, Canada.

本提案的总体目标是充分利用一种新的癌症疗法的治疗潜力。这涉及到新型放射性药物，其中包含用于癌症特异性靶向α治疗（TAT）的α发射放射性同位素，这有望彻底改变癌症治疗。然而，由于在TAT药物开发过程中对α发射器的繁琐检测，这种新疗法的开发和实施受到阻碍和延迟。我们将通过为制药行业开发一种新的先进α传感器来改变这一现状。该传感器将促进并大大简化TAT放射性药物的监测、基准测试和质量控制。该传感器将主要基于英国探测器技术，该技术是在stfc资助的加拿大TRIUMF核结构和核天体物理实验研究计划下开发的。